Topical Therapies for Rheumatoid Arthritis by Gel Ointments containing Indomethacin Nanoparticles in Adjuvant-Induced Arthritis Rat

1) Hultqvist, M.; Olofsson, P.; Gelderman, K. A.; Holmberg, J.; Holmdahl, R. A new arthritis therapy with oxidative burst inducers. PLoS. Med. 3, e348 (2006).

2) Escandell, J. M.; Recio, M. C.; Manez, S.; Giner, R. M.; Cerda, N. M.; Rios, J. L. Cucurbitacin R reduces the inflammation and bone damage associated with adjuvant arthritis in lewis rats by suppression of tumor necrosis factor-alpha in T lymphocytes and macrophages. J. Pharmacol. Exp. Ther. 320, 581-590 (2007).

3) Heyneman, C. A.; Lawless-Liday, C.; Wall, G. C. Oral versus topical NSAIDs in rheumatic diseases: A comparison. Drugs 60, 555-574 (2000).

4) Kato, S.; Takeuchi, K. Alteration of gastric ulcerogenic and healing responses in rats with adjuvant-induced arthritis. Jpn. J. Pharmacol. 89, 1-6 (2002).

5) Maiden, L.; Thjodleifsson, B.; Theodors, A.; Gonzalez, J.; Bjarnason, I. A quantitative analysis of NSAID-induced small bowel pathology by capsule enteroscopy. Gastroenterology 128, 1172-1178 (2005).

6) Kato, N.; Mashita, Y.; Kato, S.; Mitsufuji, S.; Yoshikawa, T.; Takeuchi, K. Sildenafil, an inhibitor of phosphodiesterase subtype 5, prevents indomethacin-induced small-intestinal ulceration in rats via a NO/cGMP-dependent mechanism. Dig. Dis. Sci. 54, 2346-2356 (2009).

7) Kato, S.; Ohkawa, F.; Ito, Y.; Amagase, K.; Takeuchi, K. Role of endothelial nitric oxide synthase in aggravation of indomethacin-induced gastric damage in adjuvant arthritic rats. J. Physiol. Pharmacol. 60, 147-155 (2009).

8) Nagai, N.; Fukuhata, T.; Ito, Y.; Usui, S.; Hirano, K. Involvement of interleukin 18 in indomethacin-induced lesions of the gastric mucosa in adjuvant-induced arthritis rat. Toxicology 255, 124-130 (2009).

9) Bjarnason, I. Gastrointestinal safety of NSAIDs and over-the-counter analgesics. Int. J. Clin. Pract. Suppl. 178, 37-42 (2013).

10) Helleberg, L. Clinical pharmacokinetics of indomethacin. Clin. Pharmacokinet 6, 245-258 (1981).

11) Fries, J. F.; Miller, S. R.; Spitz, P. W.; Williams, C. A.; Hubert, H. B.; Bloch, D. A. Toward an epidemiology of gastropathy associated with non-steroidal antiinflammatory drug use. Gastroenterology 96, 647-655 (1989).

12) Ricci, M.; Puglia, C.; Bonina, F.; Di, Giovanni, C.; Giovagnoli, S.; Rossi, C. Evaluation of indomethacin percutaneous absorption from nanostructured lipid carriers (NLC) : in vitro and in vivo studies. J. Pharm. Sci. 94, 1149-1159 (2005).

13) Consola, S.; Blanzat, M.; Perez, E.; Garrigues, J. C.; Bordat, P.; Rico-Lattes, I. Design of original bioactive formulations based on sugar-surfactant/non-steroidal anti-inflammatory catanionic self-assemblies: a new way of dermal drug delivery. Chemistry 13, 3039-3047 (2007).

14) Kalia, Y. N.; Naik, A.; Garrison, J.; Guy, R. H. Iontophoretic drug delivery. Adv. Drug Deliv. Rev. 56, 619-658 (2004).

15) Denet, A. R.; Vanbever, R.; Préat, V. Skin electroporation for transdermal and topical delivery. Adv. Drug Deliv. Rev. 56, 659-674 (2004).

16) Doukas, A. G.; Kollias, N. Transdermal drug delivery with a pressure wave. Adv. Drug Deliv. Rev. 56, 559-579 (2004).

17) Mitragotri, S.; Kost, J. Low-frequency sonophoresis: a review. Adv. Drug Deliv. Rev. 56, 589-601 (2004).

18) Williams, A. C.; Barry, B. W. Penetration enhancers. Adv. Drug Deliv. Rev. 56, 603-618 (2004).

19) Cevc, G. Lipid vesicles and other colloids as drug carriers on the skin. Adv. Drug Deliv. Rev. 56, 675-711 (2004).

20) Delouise, L. A. Applications of nanotechnology in dermatology. J. Invest. Dermatol. 132, 964-975 (2012).

21) Gao, X.; Cui, Y.; Levenson, R. M.; Chung, L. W.; Nie, S. In vivo cancer targeting and imaging with semiconductor quantum dots. Nat. Biotechnol. 22, 969-976 (2004).

22) Moghimi, S. M.; Hunter, A. C.; Murray, J. C. Nanomedicine: current status and future prospects. FASEB J. 19, 311-330 (2005).

23) Al-Jamal, W. T.; Al-Jamal, K. T.; Tian, B.; Cakebread, A.; Halket, J. M.; Kostarelos, K. Tumor targeting of functionalized quantum dot-liposome hybrids by intravenous administration. Mol. Pharm. 6, 520-530 (2009).

24) Boisselier, E.; Astruc, D. Gold nanoparticles in nanomedicine: preparations, imaging, diagnostics, therapies and toxicity. Chem. Soc. Rev. 38, 1759-1782 (2009).

25) Debbage, P. Targeted drugs and nanomedicine: present and future. Curr. Pharm. Des. 15, 153-172 (2009).

26) Huang, H. C.; Barua, S.; Sharma, G.; Dey, S. K.; Rege, K. Inorganic nanoparticles for cancer imaging and therapy. J. Control Release 155, 344-357 (2011).

27) Huang, X.; Peng, X.; Wang, Y.; Wang, Y.; Shin, D. M.; El-Sayed, M. A.; Nie, S. A reexamination of active and passive tumor targeting by using rod-shaped gold nanocrystals and covalently conjugated peptide ligands. ACS Nano 4, 5887-5896 (2010).

28) Ilbasmiş-Tamer, S.; Yilmaz, S.; Banoğlu, E.; Değim, I.T. Carbon nanotubes to deliver drug molecules. J. Biomed. Nanotechnol. 6, 20-27 (2010).

29) Chouly, C.; Pouliquen, D.; Lucet, I.; Jeune, J. J.; Jallet, P. Development of superparamagnetic nanoparticles for MRI: effect of particle size, charge and surface nature on biodistribution. J. Microencapsul. 13, 245-255 (1996).

30) Begley, D. J. Delivery of therapeutic agents to the central nervous system: the problems and the possibilities. Pharmacol. Ther. 104, 29-45 (2004).

31) Bareford, L. M.; Swaan, P. W. Endocytic mechanisms for targeted drug delivery. Adv. Drug Deliv. Rev. 59, 748-758 (2007).

32) Dobrovolskaia, M. A.; Aggarwal, P.; Hall, J. B.; McNeil, S. E. Preclinical studies to understand nanoparticle interaction with the immune system and its potential effects on nanoparticle biodistribution. Mol. Pharm. 5, 487-495 (2008).

33) Toy, R.; Peiris, P. M.; Ghaghada, K. B.; Karathanasis, E. Shaping cancer nanomedicine: the effect of particle shape on the in vivo journey of nanoparticles. Nanomedicine (Lond) 9, 121-134 (2014).

34) Misra, R.; Upadhyay, M.; Mohanty, S. Design considerations for chemotherapeutic drug nanocarriers. Pharm. Anal. Acta. 5, 279 (2014).

35) Nagai, N.; Ito, Y. Therapeutic effects of gel ointments containing tranilast nanoparticles on paw edema in adjuvant-induced arthritis rats. Biol. Pharm. Bull. 37, 96-104 (2014).

36) Cohen, S.; Yoshioka, T.; Lucarelli, M.; Hwang, L. H.; Langer, R. Controlled delivery systems for proteins based on poly (lactic/glycolic acid) microspheres. Pharm. Res. 8, 713-720 (1991).

37) Tomoda, K.; Terashima, H.; Suzuki, K.; Inagi, T.; Terada, H.; Makino, K. Enhanced transdermal delivery of indomethacin-loaded PLGA nanoparticles by iontophoresis. Colloids Surf. B. Biointerfaces 88, 706-710 (2011).

38) Tomoda, K.; Terashima, H.; Suzuki, K.; Inagi, T.; Terada, H.; Makino, K. Enhanced transdermal delivery of indomethacin using combination of PLGA nanoparticles and iontophoresis in vivo. Colloids Surf. B. Biointerfaces 92, 50-54 (2012).

39) Tomoda, K.; Watanabe, A.; Suzuki, K.; Inagi, T.; Terada, H.; Makino, K. Enhanced transdermal permeability of estradiol using combination of PLGA nanoparticles system and iontophoresis. Colloids Surf. B. Biointerfaces 97, 84-89 (2012).

40) Nagai, N.; Ono, H.; Hashino, M.; Ito, Y.; Okamoto, N.; Shimomura, Y. Improved corneal toxicity and permeability of tranilast by the preparation of ophthalmic formulations containing its nanoparticles. J. Oleo Sci. 63, 177-186 (2014).

41) Nagai, N.; Ito, Y. Effect of Solid Nanoparticle of Indomethacin on Therapy for Rheumatoid Arthritis in Adjuvant-Induced Arthritis Rat. Biol. Pharm. Bull. 37, 1109-1118 (2014).

42) Nagai, N.; Ito, Y.; Okamoto, N.; Shimomura, Y. A nanoparticle formulation reduces the corneal toxicity of indomethacin eye drops and enhances its corneal permeability. Toxicology 319, 53-62 (2014).

43) Franz, T. J. Percutaneous absorption on the relevance of in vitro data. J. Invest. Dermatol. 64, 190-195 (1975).

44) Sloan, K. B.; Siver, K. G.; Koch, S. A. The effect of vehicle on the diffusion of salicylic acid through hairless mouse skin. J. Pharm. Sci. 75, 744-749 (1986).

45) Yamaoka, K.; Tanigawara, Y.; Nakagawa, T.; Uno, T. A pharmacokinetic analysis program (multi) for microcomputer. J. Pharmacobiodyn. 4, 879-885 (1981).

46) Muller, B. W.; Brauns, U. Solubilization of drugs by modified b-cyclodextrins. Int. J. Pharm. 26, 77-88 (1985).

47) Kristinsson, J. K.; Fridriksdottir, H.; Thorisdottir, S.; Sigurdardottir, A. M., Stefansson, E.; Loftsson, T. Dexamethasone-cyclodextrin-polymer co-complexes in aqueous eye drops. Aqueous humor pharmacokinetics in humans. Invest. Ophthalmol. Vis. Sci. 37, 1199-1203 (1996).

48) Nishihata, T.; Kamada, A.; Sakai, K.; Takahashi, K.; Matsumoto, K.; Shinozaki, K.; Tabata, Y.; Keigami, M.; Miyagi, T.; Tatsumi, N. Percutaneous absorption of diclofenac in rats and humans: aqueous gel formulation. Int. J. Pharm. 46, 1-7 (1988).

49) Ahmed, T. A.; Ibrahim, H. M.; Ibrahim, F.; Samy, A. M.; Fetoh, E.; Nutan, M. T. In vitro release, rheological, and stability studies of mefenamic acid coprecipitates in topical formulations. Pharm. Dev. Technol. 16, 497-510 (2011).

50) Billingham, M. E. Models of arthritis and the search for anti-arthritic drugs. Pharmacol. Ther. 21, 389-428 (1983).

51) Sakuma, S.; Nishigaki, F.; Magari, K.; Ogawa, T.; Miyata, S.; Ohkubo, Y.; Goto, T. FK506 is superior to methotrexate in therapeutic effects on advanced stage of rat adjuvant-induced arthritis. Inflamm. Res. 50, 509-514 (2001).

52) Kato, S. Changes in ulcerogenic response to non-steroidal anti-inflammatory drugs (NSAIDs) in adjuvant arthritic rats. Yakugaku Zasshi 121, 743-751 (2001).